Dr. William G. Wierda, M.D., PHD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 268
Licensed in Texas since 2002, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license L3873 (first issued 2002; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 268
- Services billed
- 798
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 267 | 48 |
| Established patient office or other outpatient visit, 30-39 minutes | 225 | 160 |
| Established patient office or other outpatient visit, 40-54 minutes | 192 | 77 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Venclexta (venetoclax) | 31 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Houston, TX | 28 |
| Calquence (acalabrutinib maleate) | 19 |
| Levofloxacin Other prescribers in Houston, TX | 17 |
| Posaconazole | 13 |
| Allopurinol Other prescribers in Houston, TX | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 9 payments worth $1,058 in total to this clinician.
| Eli Lilly and Company | $520 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $153 |
| Lilly USA, LLC | $133 |
| AbbVie Inc. | $127 |
| Sobi, Inc | $104 |
| Celgene Corporation | $21.14 |
| Food and Beverage | $538 |
|---|---|
| Travel and Lodging | $520 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Oct 2, 2025 | Travel and Lodging travel to NEW YORK, TX · in-kind | $520 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $4,837,300 in research payments for these studies, mostly to the institutions running them.
- A Randomized Phase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) ? Early Obinutuzumab (OBIN) for Patients with Chronic Lymphocytic Leukemia (CLL)
AstraZeneca Pharmaceuticals LP - An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Celgene Corporation - Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie Inc. · Active, not recruiting · NCT05753501 - A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company · Completed · NCT03740529 - A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie Inc. · Active, not recruiting · NCT06291220 - An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
E.r. Squibb & Sons, L.l.c. - Safety Efficacy and Pharmacokinetics of Mosunetuzumab in R R CLL
Genentech, Inc. - Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
AbbVie Inc. · Active, not recruiting · NCT03229200 - A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Acerta Pharma LLC - A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination with ACP-319 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
Acerta Pharma LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.